Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are Associated with Susceptibility and Chemotherapy Response in Non-small-cell Lung Cancer Patients

Li, WeiYing; Yue, Wentao; Zhang, Lína; Zhao, Xiaoting; Ma, Li; Yang, Xuehui; Zhang, Chunyan; Wang, Yue; Gu, Meng

doi:10.1007/s00408-011-9338-8

Cited by 40 publications

(30 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, after screening of the titles and abstracts of all 114 articles, 50 were excluded. Of the 64 potentially relevant articles identified for further assessment, one article (Wu et al, 2003) was excluded because it did not provide sufficient data about the distribution of GSTM1 genotype, 18 Hu et al, 1998;Chen et al, 1999;Gu et al, 2004;Luo et al, 2004;Ye et al, 2005;Zeng et al, 2005;Chang et al, 2006;Wang et al, 2007;Chang et al, 2009;Li et al, 2011;Li et al, 2012;Ma et al, 2013) were excluded because they concerned duplicate subjects. Finally, a total of 45 articles (47 studies) (Ge et al, 1996;Gao & Zhang, 1999;Lan et al, 2000;London et al, 2000;Chen et al, 2001;Zhao et al, 2001;Chan et al, 2002;Lu et al, 2002;Zhang et al, 2002a;Chen et al, 2003;Xian et al, 2003;Chan-Yeung et al, 2004;Li et al, 2004;Liang et al, 2004;Yang et al, 2004;Chan et al, 2005;Li et al, 2005a;Qiao et al, 2005;Wang et al, 2005;Chen et al, 2006;Qian et al, 2006;Yao et al, 2006;Gu et al, 2007;Lei et al, 2007;Liu et al, 2008;…”

Section: Study Selectionmentioning

confidence: 99%

GSTM1 Polymorphisms and Lung Cancer Risk in the Chinese Population: a Meta-Analysis Based on 47 Studies

Chen

Xu²,

Xu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Although a number of studies have been conducted on the association between GSTM1 polymorphisms and lung cancer in China, this association remains elusive and controversial. To clarify the effects of GSTM1 polymorphisms on the risk of lung cancer, a meta-analysis was performed in the Chinese population. Related studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) up to 5th April 2014. A total of 45 articles (47 studies) including 6,623 cases and 7,865 controls were involved in this meta-analysis. Overall, a significant association (OR = 1.45, 95%CI: 1.32-1.60) was found between the null GSTM1 and lung cancer risk when all studies in Chinese population pooled into the meta-analysis. In subgroup analyses stratified by quality score, geographic area and source of controls, the same results were observed under all the models. This meta-analysis showed that the null GSTM1 may be a potential biomarker for lung cancer risk in Chinese, but further studies with gene-gene and gene-environment interactions are required for definite conclusions.

show abstract

Section: Study Selectionmentioning

confidence: 99%

GSTM1 Polymorphisms and Lung Cancer Risk in the Chinese Population: a Meta-Analysis Based on 47 Studies

Chen

Xu²,

Xu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Studies investigating the effect of the CYP2E1*5B polymorphism on NSCLC risk also reported inconsistent results (17,(28)(29)(30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer

Ada

Bilgen

Volkan

et al. 2016

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Genetic polymorphisms in tumour suppressor genes and genes encoding xenobiotic metabolising enzymes alter the activity of their corresponding enzymes and are important individual susceptibility factors for NSCLC. Because of the lack of information in literature, the aim of our study was to investigate the role of the tumour suppressor gene TP53 (Arg72Pro) and the xenobiotic metabolising CYP2E1*5B gene polymorphisms on the risk of NSCLC development. The study population consisted of 172 patients and 172 controls (156 men and 16 women in each group). Genetic polymorphisms were determined with real-time polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (PCR-RFLP). Multivariate analysis showed a significant association with NSCLC for the combination between the TP53 codon72 Arg/Pro and the Pro/Pro genotypes (OR 2.21, 95 % CI 1.39-3.51; p=0.001). We also analysed whether combinations of these gene variants with GSTM1, GSTT1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) gene polymorphisms were associated with the NSCLC risk. A significant increase in the risk was observed for the following combinations: TP53 codon72 variant with GSTM1 null (OR 2.22, 95 % CI 1.23-4.04; p=0.009), GSTT1 null (OR 2.98, 95 % CI 1.49-5.94; p=0.002), and GSTP1 (Ala114Val) variant genotypes (OR 3.38, p=0.002). Further studies with larger samples are needed to verify these findings. KEY WORDS: carcinogen metabolism; CYP2E1; genetic polymorphism; GST; NSCLCLung cancer is the most common cancer type in the world, which affects men in particular. It is also the leading cause of death among cancers (1). Histologically, about 80 % of lung cancers are non-small cell lung carcinomas (NSCLC). The inbuilt phase I and II biotransformation enzyme systems inactivate environmental carcinogens, especially those present in tobacco smoke, depending on the regulating polymorphisms. Epidemiological studies show that genetic differences and interactions among genetic variants might modify lung cancer susceptibility (2, 3). Therefore, it is important to identify individual genetic and acquired factors that modify lung cancer risk in order to develop preventive strategies based on this information. This is particularly true for identifying polymorphisms of tumour suppressor genes and xenobiotic metabolising enzyme genes. The TP53 tumour suppressor gene is an essential regulator of the cell-cycle arrest, DNA repair, and apoptosis (4). An important single nucleotide polymorphism detected in TP53 is Arg72Pro. This allele has been shown to decrease the activity of the corresponding protein, which is crucial for the apoptotic function of TP53 (5, 6). Recent studies have reported the association between this polymorphism and lung cancer (7-11).CYP2E1 is an important phase I biotransformation enzyme that transforms N-nitrosamines, vinyl chloride, and benzene in tobacco smoke into mutagenic and carcinogenic metabolites (12). In NSCLC patients it has been fou...

show abstract

“…However, individuals not exposed to these risk factors can also develop lung cancer, indicating that a difference in cancer susceptibility exists among individuals (Ada et al, 2012). Previous studies indicate that genetic polymorphisms in the glutathione S-transferase M1 (GSTM1) gene may affect the risk of lung cancer (Nakachi et al, 1993;Cao et al, 2004;Chen et al, 2004aChen et al, , 2012Atinkaya et al, 2012;Han et al, 2012;Li et al, 2012;Liang et al, 2012;Liu et al, 2012). Subjects who have inherited specific variants in the GSTM1 gene may be susceptible to the effects of chemical carcinogens and thus at a high risk of developing lung cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Seidegård et al (1986) first reported the association between GSTM1 deficiency and lung cancer. Since then, there have been more than 40 studies examining this topic (Li et al, 2012;Liang et al, 2012;Liu et al, 2012;López-Cima et al, 2012;Yao et al, 2012). However, there is disagreement among the results of these studies.…”

Section: Introductionmentioning

confidence: 99%

Association between GSTM1 polymorphisms and lung cancer: an updated meta-analysis

Liu¹,

F²,

Chen³

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT.The relationship between glutathione S-transferase M1 (GSTM1) genetic polymorphisms and lung cancer has been reported previously. However, the results are not consistent. Therefore, to clarify the association between GSTM1 polymorphisms and lung cancer, we performed a meta-analysis based on published studies. We used the Revman 5.0 software to perform literature retrieval, article selection, data collection, and statistical analysis. We utilized a random-effect model to pool the odds ratios (ORs) and 95% confidence intervals (CIs). A total of 38 eligible studies including 5737 lung cancer patients and 6843 cancer-free control subjects were analyzed. We found no association between GSTM1 genetic polymorphisms and lung cancer risk (OR = 1.15, 95%CI = 0.98-1.36, P = 0.08). Including only Chinese individuals, we found no association between GSTM1 genetic polymorphisms and lung cancer risk (OR = 1.13, 95%CI = 0.97-1.32, P = 0.13). In conclusion, we found that GSTM1 polymorphisms are not associated with lung cancer risk.

show abstract

Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are Associated with Susceptibility and Chemotherapy Response in Non-small-cell Lung Cancer Patients

Cited by 40 publications

References 27 publications

GSTM1 Polymorphisms and Lung Cancer Risk in the Chinese Population: a Meta-Analysis Based on 47 Studies

GSTM1 Polymorphisms and Lung Cancer Risk in the Chinese Population: a Meta-Analysis Based on 47 Studies

Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer

Association between GSTM1 polymorphisms and lung cancer: an updated meta-analysis

Contact Info

Product

Resources

About